J.P. Morgan Day 1: Pharma Execs Offer Big Talk Instead Of Big Deals

 
• By Scrip Team

Daily notebook from the virtual J.P. Morgan Healthcare Conference: business development is top of mind for BMS, Merck, J&J and Pfizer, while Novartis, Moderna and Regeneron talk about next steps. Bayer looks to minimize Xarelto patent expiry, a new chief exec debuts for Alnylam and EY suggests 2022 will be another year of bolt-on deals. 

J.P. Morgan Daily Notebook 2022 Day 1
• Source: Alamy

More from Business

More from Scrip